Description

Endomysial antibodies (EMA) IgA, detected by indirect immunofluorescence assay (IFA), are specific autoantibodies associated with autoimmune diseases, particularly celiac disease. These antibodies target the endomysium, which is a thin layer of connective tissue that surrounds individual muscle fibers. In celiac disease, the immune system mistakenly attacks the lining of the small intestine in response to gluten consumption, and this attack can lead to damage to the endomysium.

The indirect immunofluorescence assay (IFA) is a laboratory technique used to detect the presence of specific antibodies in a patient’s blood sample. In the case of endomysial antibodies, this assay involves applying a patient’s serum to a slide containing tissue sections (often from the small intestine of a primate or human) and then adding a fluorescent-tagged antibody that binds to any endomysial antibodies present in the sample. Under a fluorescent microscope, if endomysial antibodies are present, they will produce a characteristic pattern of fluorescence around the muscle fibers.

Testing for endomysial antibodies IgA via IFA is an important tool in diagnosing celiac disease, particularly in cases where other diagnostic tests, such as serological tests for anti-tissue transglutaminase (tTG) antibodies or anti-endomysial antibodies (EMA) IgA, yield ambiguous results.